Any current/future new fundraising through debt or equity?

Kaya Limited has approval for a rights issue of up to INR 300 crores. The rights issue process is expected to start after completion of the Kaya DMCC sale, pending local authority approval. The raised funds from the rights issue will be used to strengthen the balance sheet by repaying loans. Using cash from the rights issue will enable accelerated clinic expansion without additional borrowing. Management does not currently share forward-looking statements on profitability or margin targets but expects improvement through expansion and financial restructuring. No specific mention of new debt fu

Any current/future capex/capital investment/strategic investment?

Kaya Limited is currently finalizing the application of funds from the rights issue, with details to be shared in due course (Page 8). The company invested in 29 new dermatology machines in Q2, covering Anti-Ageing, Acne, Body, Hair Care, and Laser Hair Reduction services to uplift customer experience and outcomes (Page 3). Clinic Refresh and Brand Refresh programs are ongoing, including relocating 7 clinics since the start of FY '25 and renovating 4 clinics in Q2 (Page 3). Expansion plans are underway with accelerated clinic openings, though exact numbers for next year are not disclosed yet (

Future growth expectations in sales/revenue/volumes?

Kaya Limited is focusing on accelerating expansion through a combination of organic and inorganic growth, supported by a rights issue to strengthen the balance sheet. Revenue growth is currently modest, with a 5% growth in the Clinics business and 4% growth in product sales at clinics in Q2 FY'25 versus the previous year. New customer acquisition is in double digits, although overall customer count has declined due to a drop in existing customers. Marketing efforts will continue as customer count and footfall remain critical for growth. The partnership with Marico aims to scale Kaya’s product

Future growth expectations in earnings/operating earnings/profits/EPS?

Kaya Limited aims for a path to profitability driven by clinic business scaling both organically and inorganically. Almost all clinics (except 3) are EBITDA positive; clinic business has approx. 26-27% EBITDA margin. Expansion plans are to be accelerated post rights issue, which will strengthen the balance sheet and reduce borrowing. Rights issue up to INR 300 crores approved; timing dependent on completion of Kaya DMCC sale. Marketing and corporate costs are expected to remain steady; focus is on driving customer acquisition and clinic footfall. New clinics take ~1.5-2 years to achieve operat

Kaya LtdQ2 FY25Leisure Services

Kaya Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹312.4Market Cap: ₹474 CrSector: Leisure Services

Management growth scorecard

Revenue

Category 4

Margin

N/A

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 4

Kaya Limited is focusing on accelerating expansion through a combination of organic and inorganic growth, supported by a rights issue to strengthen the balance sheet.
Revenue growth is currently modest, with a 5% growth in the Clinics business and 4% growth in product sales at clinics in Q2 FY'25 versus the previous year.
New customer acquisition is in double digits, although overall customer count has declined due to a drop in existing customers.
Marketing efforts will continue as customer count and footfall remain critical for growth.
The partnership with Marico aims to scale Kaya’s product range beyond clinics to increase brand visibility, indirectly supporting clinic footfall.
Kaya targets accelerated growth post-rights issue without further borrowing.
Clinic refurbishments and launches continue to improve customer experience and support revenue growth.
Overall, they expect growth momentum to pick up as expansion efforts gain pace and customer acquisition initiatives bear fruit.

Margin guidance

Kaya Limited aims for a path to profitability driven by clinic business scaling both organically and inorganically.
Almost all clinics (except 3) are EBITDA positive; clinic business has approx. 26-27% EBITDA margin.
Expansion plans are to be accelerated post rights issue, which will strengthen the balance sheet and reduce borrowing.
Rights issue up to INR 300 crores approved; timing dependent on completion of Kaya DMCC sale.
Marketing and corporate costs are expected to remain steady; focus is on driving customer acquisition and clinic footfall.
New clinics take ~1.5-2 years to achieve operational breakeven; payback period is 3-4 years.
Anticipated revenue growth of around 5% in clinics with improving operational efficiencies.
No specific forward EPS or profit numbers disclosed due to forward-looking statement restrictions.
Growth in associated product categories (Hair Care, Body Care) and increased brand visibility via partnership with Marico expected to support earnings expansion.

See what Kaya Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Kaya Limited has approval for a rights issue of up to INR 300 crores.
The rights issue process is expected to start after completion of the Kaya DMCC sale, pending local authority approval.
The raised funds from the rights issue will be used to strengthen the balance sheet by repaying loans.
Using cash from the rights issue will enable accelerated clinic expansion without additional borrowing.
Management does not currently share forward-looking statements on profitability or margin targets but expects improvement through expansion and financial restructuring.
No specific mention of new debt fundraising was made during the call; focus is on equity fundraising via the rights issue.

Order book

The transcript and presentation details provided do not mention any information related to the current or expected order book or pending orders for Kaya Limited. The discussion primarily focuses on financial performance, clinic profitability, expansion plans, rights issue, and operational updates. No specific data on order backlog or pending orders is disclosed in the Q2 FY '25 earnings call or investor presentation materials.

See what Kaya Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Kaya Limited is currently finalizing the application of funds from the rights issue, with details to be shared in due course (Page 8).
The company invested in 29 new dermatology machines in Q2, covering Anti-Ageing, Acne, Body, Hair Care, and Laser Hair Reduction services to uplift customer experience and outcomes (Page 3).
Clinic Refresh and Brand Refresh programs are ongoing, including relocating 7 clinics since the start of FY '25 and renovating 4 clinics in Q2 (Page 3).
Expansion plans are underway with accelerated clinic openings, though exact numbers for next year are not disclosed yet (Page 6).
The rights issue, approved up to INR 300 crores, is expected to strengthen the balance sheet and fund expansion without additional borrowing (Pages 6-7).
Strategic collaboration with Marico to scale Kaya's product range outside clinics aims to indirectly boost clinic footfall and brand visibility (Page 4).

Track Kaya Ltd — get its next earnings analysis in your feed

How does Kaya Ltd rank vs peers in Leisure Services?

Pro feature

ThisKaya Ltd

Rev 4

See where Kaya Ltd sits in Leisure ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Kaya Ltd rank in Leisure Services?

Compare Kaya Ltd against every Leisure Services company (Q2 FY25) on revenue, margins and earnings-call signals.

View Leisure Services leaderboard →

What Kaya Ltd's management said in earlier quarters

Others in Leisure Services this season

Delta Corp (Q2 FY27)
For the quarter ended 30th September 2026, consolidated net sales/revenue from operations was ₹159.34 crores, down from ₹182.76 crores in the same quarter last…
Le Travenues Technology Ltd (Q2 FY27)
Gross Transaction Value (GTV): ₹5,304.47 crores, up 22% YoY . Key investor presentation takeaways from Le Travenues Technology Ltd's Q2 FY27 investor presentati
Ventive Hospitality Ltd (Q2 FY26)
Direct booking channels growing, especially in India (currently 60% of sales) and Maldives, enhancing margins and revenues. Key concall takeaways from Ventive…
Imagicaaworld Entertainment Ltd (Q2 FY26)
41.8 Cr, up 4.6% from Rs. Key investor presentation takeaways from Imagicaaworld Entertainment Ltd's Q2 FY26 investor presentation — and how it ranks against se

Compare:vs Indian Hotels Co Ltd vs Indian Railway Catering & Tourism Corporation Ltd vs ITC Hotels

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →